A Multicenter Observational Study of the Response to Rituximab (MabThera®) in Seropositive Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to Treatment With One or More Tumor Necrosis Factor Inhibitors (TNFi)
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms POSITIVE
- Sponsors Roche
- 01 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 01 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.
- 01 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Sep 2015, as reported by ClinicalTrials.gov.